

Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023

<https://marketpublishers.com/r/G76D1EEAE0AEN.html>

Date: September 2017

Pages: 220

Price: US\$ 2,800.00 (Single User License)

ID: G76D1EEAE0AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on the ongoing market and clinical development in HPV drug market. Report highlights the trends in the global HPV drug market and gives detailed overview on the HPV drug clinical pipeline by phase, drug class and mode of action. As per report findings, there are 9 HPV drugs commercially available in the market and 78 drugs are in multiple phases of clinical pipeline. Majority of the HPV drugs are in Preclinical phase of development followed by Phase-II clinical trials.

In the past decade, there have been remarkable advances in the understanding of the natural history of human papillomavirus (HPV) infection and its role as the major risk factor in the development of cervical and other anogenital cancers, which has led to increased research and development in the HPV drug segment; thus leading to the introduction of excellent and promising therapeutics in the Human Papilloma virus drug segment.

Among the various therapeutics currently available for Human Papilloma virus infection, is the Human Papilloma Virus Vaccine which is currently the dominant form of medication in the HPV therapeutic segment. These Vaccines are considered to be the most superior kinds of therapeutics due to their ability to provide long term protection from Human Papilloma Virus. Apart from being safe and effective, these have been in wide use in the vaccination of preteen girls and boys in US and other developed countries to ensure their long term protection and prevention from exposure to the Human Papilloma virus.

Further, these vaccines also ensure high efficacy in preventing genital warts, anal cancer, cervical cancer, vulvar cancer and vaginal cancer which are widely known to be caused by certain types of human papilloma virus. It has also been used in the prevention of lesions that are caused by the Human Papilloma virus which can lead to the above mentioned complications.

“Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023”
Report Highlights:

Global Human Papillomavirus Infection Market Analysis

Global Human Papillomavirus Infection Drug Market Dynamics

Clinical Insight on Approved Drugs for Treating Human Papillomavirus Infection

Global Human papillomavirus Infections Drug Clinical Pipeline by Company & Phase

Global Human Papillomavirus Infection Drug Market Future Perspective

The next decade in research against HPV infections should be geared up to fill in gap in knowledge of HPV gene expression and its regulation. The future treatment approaches is coupled with application of next generation sequencing and proteomic technologies, screening of new, more extensive small molecule libraries to look for molecule inhibitory to either the virus replication cycle or to tumor formation. The RNA based therapies should advance the prospects of new anti-HPV treatments to improve the disease.

The increase in understanding of new drugs, development of new adjuvants along with increasing funding from private and public sector will drive the growth of HPV infection drug market in near future. It is expected that there will be more efforts involved in the R&D and commercialization of therapeutic HPV vaccines driven by the increasing prevalence of HPV associated malignancies across the globe.

Contents

1. INTRODUCTION TO HUMAN PAPILLOMAVIRUS INFECTION

- 1.1 Overview
- 1.2 Pathogenicity & Diversity of Human Papillomavirus
 - 1.2.1 Alpha Papillomaviruses
 - 1.2.2 Beta Papillomaviruses
 - 1.2.3 Gamma Papillomaviruses

2. PATHOPHYSIOLOGY OF HUMAN PAPILLOMAVIRUS

- 2.1 Life Cycle of Human Papillomavirus
 - 2.1.1 Primary Infection of Epidermis Layer
 - 2.1.2 Genome Maintenance
 - 2.1.3 Proliferative Phase
 - 2.1.4 Viral Genome Amplification
 - 2.1.5 Virus Assembly & Release
- 2.2 Molecular Mechanism of Human Papillomavirus to Induce Disease

3. RESPONSE OF IMMUNE SYSTEM AGAINST HUMAN PAPILLOMAVIRUS

- 3.1 Innate Immunity
- 3.2 Adaptive Immunity

4. CLINICAL MANAGEMENT STRATEGIES AGAINST HUMAN PAPILLOMAVIRUS INFECTION

- 4.1 Vaccination Approach for Human Papillomavirus
- 4.2 Therapeutic Drugs Targets
 - 4.2.1 Interferon
 - 4.2.2 RNA Interference based Therapies
 - 4.2.3 Natural or Herbal Derivatives

5. EMERGING THERAPIES FOR TREATMENT OF INFECTION

- 5.1 Live Vector based Vaccines
- 5.2 Protein or Peptide based Vaccines
- 5.3 Nucleic Acid based Vaccines

5.4 Whole Cell based Vaccines

6. APPROVED DRUGS FOR TREATING HUMAN PAPILLOMAVIRUS INFECTION: CLINICAL, DRUG CLASS & PATENT INSIGHT

6.1 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)

6.2 Interferon alpha-2b (Intron A, Viraferon & Virtron)

6.3 Tretinoin (Acnisdin Retinoico, Avita, Dermojuventus, Loderm Retinoico, Retirides, Vesanoid, Vitamin-A Acid & Vitanol)

6.4 Imiquimod (Aldara, Beselna Cream 5%, Vyloma & Zyclara)

6.5 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix)

6.6 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)

6.7 Interferon-alpha-n3 (Alferon LDO, Alferon N, Alferon N Gel, Alferon N Injection, Alferon N LDO, Altemol & Naturaferon)

6.8 Polyphenon E (Polyphenon E & Veregen)

6.9 Interferon Gamma Biosimilar (Ingaron)

7. GLOBAL HUMAN PAPILLOMAVIRUS INFECTION MARKET ANALYSIS

7.1 Introduction to Infectious Disease Market

7.2 Global Human Papillomavirus Market Analysis

8. GLOBAL HUMAN PAPILLOMAVIRUS INFECTION DRUG MARKET DYNAMICS

8.1 Favorable Parameters

8.2 Challenges to Market Growth

9. GLOBAL HUMAN PAPILLOMAVIRUS INFECTION DRUG MARKET FUTURE PERSPECTIVE

10. GLOBAL HUMAN PAPILLOMAVIRUS INFECTIONS DRUG CLINICAL PIPELINE BY COMPANY & PHASE

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-II/III

10.7 Phase-III

11. COMPETITIVE LANDSCAPE

11.1 3M Pharmaceuticals

11.2 Aclaris Therapeutics

11.3 Mylan Pharmaceuticals

11.4 Biogen Idec

11.5 Cutanea Life Sciences

11.6 Hemispherx

11.7 Inovio Pharmaceuticals

11.8 ISA Pharmaceuticals

11.9 Lees Pharmaceutical Holdings

11.10 MedImmune

11.11 Merck

11.12 Nielsen BioSciences

11.13 Novan

List Of Figures

LIST OF FIGURES

Figure 1-1: Structural Components of Viral Particles

Figure 1-2: Fundamental Constituents of Human Papillomavirus

Figure 1-3: Classification & Diversity of Human Papillomavirus

Figure 2-1: Life Cycle of Human Papillomavirus to Cause the Infection

Figure 2-2: Multistep Model of Cancer Development by Human Papillomavirus

Figure 3-1: HPV Infection Model & Activation of Innate Immune Response

Figure 3-2: Adaptive Immune Response to Human Papillomavirus Infection

Figure 4-1: Clinical Management Strategies for Treating Human Papillomavirus Infections

Figure 4-2: HPV L1 VLP Vaccine Mechanism of Action

Figure 4-3: Response of Interferons with Human Papillomavirus

Figure 7-1: Global – Infectious Disease Diagnostic Market Growth Estimation (US\$ Million), 2016-2023

Figure 7-2: Global Infectious Therapeutics Market Growth (US\$ Billion), 2016-2023

Figure 7-3: Global Viral Infections Market Growth Estimation (US\$ Billion), 2016-2023

Figure 7-4: Global - HPV Therapeutics Market (US\$ Billion), 2016-2023

Figure 7-5: Global - Human Papillomavirus Infection Drug Pipeline by Phase (%), 2017 till 2023

Figure 7-6: Global - Human Papillomavirus Infection Drug Pipeline by Phase (Number), 2017 till 2023

Figure 7-7: Global – Active & Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (%), 2017 till 2023

Figure 7-8: Global – Active & Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (Number), 2017 till 2023

Figure 8-1: Global - Favorable Parameters to Human Papilloma Virus Market Growth

Figure 8-2: Global - Challenges to Human Papilloma Virus Infection Development

List Of Tables

LIST OF TABLES

Table 3-1: List of RNA Studies Targeting HPV E6 and E7

Table 3-2: Molecular Targeting HPV & Host Cellular Factors Interaction Using Natural & Herbal Derivatives

COMPANIES

3M Pharmaceuticals, Aclaris Therapeutics, Mylan Pharmaceuticals, Biogen Idec, Cutanea Life Sciences, Hemispherx, Inovio Pharmaceuticals, ISA Pharmaceuticals, Lees Pharmaceutical Holdings, MedImmune, Merck, Nielsen BioSciences, Novan

I would like to order

Product name: Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023

Product link: <https://marketpublishers.com/r/G76D1EEAE0AEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G76D1EEAE0AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970